Currently Viewing:
ISPOR 2018
Dr Harlan Krumholz Outlines the Impact of New Technology and Innovations on Healthcare Delivery
May 21, 2018
Value Assessments Are Just One Tool in the Decision-Maker's Toolkit, Panel Says
May 21, 2018
Transforming Healthcare: Boosting Real-World Evidence With Digital Health
May 21, 2018
Sally Okun: It's Time to Empower the Health Data Being Collected
May 21, 2018
Dr Clifford Goodman Discusses the Challenge of Valuing New, Expensive Therapies for Rare Diseases
May 22, 2018
Currently Reading
All-Cause Healthcare Payments Substantial for Younger Adults With Depression, and Other Poster Findings at ISPOR
May 22, 2018
Dr Adrian Hernandez Highlights the Use of Real-World Evidence and Current Barriers
May 22, 2018
Panelists Give Payer, Patient, and Economist Perspectives on High-Cost Drugs for Rare Diseases
May 23, 2018
Dr Steven Pearson Highlights the Challenge of Evaluating New Interventions That Cure Diseases
May 23, 2018
Dr Ejim Mark: Digital Health Runs the Risk of Exacerbating Disparities
May 23, 2018
Value Assessments in the Age of Personalized Medicine May Require a Cultural Shift, Panel Says
May 23, 2018
Valuation Challenges and Ethical Implications of Cures
May 23, 2018
Sally Okun: Using Digital Health Improvements to Include the Patient Voice in Healthcare
June 14, 2018
Dr Harlan Krumholz on Using New Technologies, Data Generation to Prevent or Address Epidemics
June 18, 2018
Dr Adrian F. Hernandez on the Future of Real-World Evidence
June 20, 2018
Sally Okun Outlines What Patients Define as Good Care
June 26, 2018
Dr Ejim Mark: Challenges With and Protecting the Increasing Amount of Health Data
June 27, 2018
Dr Harlan Krumholz: How Healthcare Can Better Implement New Technologies
June 29, 2018
Dr Adrian F. Hernandez: Mapping Human Health Through Project Baseline
July 03, 2018
Sally Okun on How Informed Patients Feel When Starting Treatment After a New Diagnosis
July 09, 2018
Dr Clifford Goodman on Progress With the Move to Value-Based Payments
July 09, 2018
Dr Clifford Goodman Discusses How Healthcare Should Address Social Determinants of Health
July 20, 2018
Dr Harlan Krumholz on Barriers Preventing Healthcare From Using Data to Improve Care
August 01, 2018

All-Cause Healthcare Payments Substantial for Younger Adults With Depression, and Other Poster Findings at ISPOR

Laura Joszt
Posters presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, highlighted healthcare costs for patients with treatment-resistant depression, off-label drug use in children with depressive disorder, and incidence of depression in patients diagnosed with late-stage cancer.
This page contains sponsored advertising.

Posters presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, highlighted healthcare costs for patients with treatment-resistant depression, off-label drug use in children with depressive disorder, and incidence of depression in patients diagnosed with late-stage cancer.

Patients experiencing episodes of major depressive disorder (MDD) that have not responded to at least 2 adequate lines of depression therapy are defined as having treatment-resistant depression (TRD). A study presented at the ISPOR meeting1 used data from Truven Health MarketScan Commercial and Medicare Supplemental Databases between October 1, 2008, and September 30, 2016, on patients with TRD who were 18 years or older, newly diagnosed with MDD, and newly treated with 3 or more courses of depression therapy. The third course of therapy served as the TRD index date.

In total, there were 1112 patients with TRD analyzed in the study. They were continuously enrolled for 12 months from baseline before the first course of therapy and followed for 12 months after their TRD index date (the time of the third course of therapy).

The researchers found that the mean total annual all-cause healthcare payments were $10,161 per patient in the follow-up period. More than one-third ($3423) were outpatient payments. They also found that being younger than age 65, being obese and having pain at baseline, having a higher Charlson comorbidity score (2 or higher), and having baseline resource use (emergency department visit, outpatient visit, or other visit) were associated with higher all-cause healthcare payments during the follow-up period.

The authors concluded that the annual all-cause healthcare payments in the 12 months after being defined as having TRD can be substantial for younger adults with obesity or pain. “Efforts to reduce this economic burden are warranted,” the authors concluded.

A second poster2 at ISPOR analyzed off-label drug use in children and adolescents with major depression. Currently, there are limited FDA-approved medications to treat depression in the pediatric population. As a result, off-label drug use is common, but “healthcare providers should be aware that its safety and efficacy in pediatric patients have not been fully established,” the authors noted.

The population-based study used data from 2010 to 2014 from the National Ambulatory Medical Care Survey. Among the 23.3 million outpatient visits with depression, 5.5% were children. Of those visits, 82.4% received at least 1 off-label medication with selective serotonin reuptake inhibitors being the most frequently used off label, followed by phenylpiperazine and atypical antipsychotics.

“It is important for FDA and researchers to remain committed to keeping pediatric drug development a high priority and to ensuring those drugs are appropriately labeled for children,” the authors concluded.

Finally, a third study3 looked at trends of depression among patients with late-stage cancer. Depression is one of the most common illnesses among patients with cancer, and this poster sought to understand the demographic profile on the incidence of depression after the diagnosis of late-stage cancer.

More than 123,000 patients diagnosed with late-stage breast, prostate, lung, or colorectal cancer between 2001 to 2013 in the Surveillance, Epidemiology, and End Results Medicare-linked database. The researchers found the incidence of depression after a late-stage cancer diagnosis increased from 13.2% in 2001 to 21.4% in 2013. Furthermore, the data showed that non-Hispanic whites and women were most likely to be diagnosed with depression during the mean follow-up of 6.6 months after diagnosis.

The analysis of racial/ethnic groups found 17.1% of non-Hispanic whites, 13.3% of non-Hispanic blacks, and 10.7% of Hispanics were diagnosed with depression. Nearly one-fifth (19.3%) of women were diagnosed with depression compared with 13.9% of men.

“The consideration of racial/ethnic and gender status in depression prevention and diagnosis among cancer patients should be discussed as a matter of importance to ensure that there is no diagnosis bias among men, non-Hispanic blacks, and Hispanics,” the authors concluded.

References

1. Sussman M, O’Sullivan A, Shah A, Menzin J, Olfson M. Predictors of all-cause healthcare payments among patients with treatment-resistant major depressive disorder. Presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting. May 22, 2018; Baltimore, Maryland. Abstract PMH23.

2. Lai L, Vuong D, Ting A, et al. Off-label drug use in children and adolescents with depressive disorder. Presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting. May 22, 2018; Baltimore, Maryland. Abstract PIH41.

3. Huo J, Hong Y, Xiao H, Wilkie DJ. Patterns of post-diagnosis depression among late-stage cancer patients: do racial/ethnic and gender disparities exist? Presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting. May 22, 2018; Baltimore, Maryland. Abstract PCN39.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up